Optimal dose of tirzepatide for type 2 diabetes mellitus: A meta-analysis and trial sequential analysis
出版年份 2022 全文链接
标题
Optimal dose of tirzepatide for type 2 diabetes mellitus: A meta-analysis and trial sequential analysis
作者
关键词
-
出版物
Frontiers in Cardiovascular Medicine
Volume 9, Issue -, Pages -
出版商
Frontiers Media SA
发表日期
2022-08-31
DOI
10.3389/fcvm.2022.990182
参考文献
相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。- Inflammation in obesity, diabetes, and related disorders
- (2022) Theresa V. Rohm et al. IMMUNITY
- Effect of Subcutaneous Tirzepatide vs Placebo Added to Titrated Insulin Glargine on Glycemic Control in Patients With Type 2 Diabetes
- (2022) Dominik Dahl et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Gut Microbiota: An Important Player in Type 2 Diabetes Mellitus
- (2022) Zheng Zhou et al. Frontiers in Cellular and Infection Microbiology
- Trends in Antidiabetic Drug Discovery: FDA Approved Drugs, New Drugs in Clinical Trials and Global Sales
- (2022) Amelia D. Dahlén et al. Frontiers in Pharmacology
- Gut microbiota-derived metabolites as key actors in type 2 diabetes mellitus
- (2022) Leilei Du et al. BIOMEDICINE & PHARMACOTHERAPY
- Management of type 2 diabetes with the dual GIP/GLP-1 receptor agonist tirzepatide: a systematic review and meta-analysis
- (2022) Thomas Karagiannis et al. DIABETOLOGIA
- Tirzepatide cardiovascular event risk assessment: a pre-specified meta-analysis
- (2022) Naveed Sattar et al. NATURE MEDICINE
- Effects of subcutaneous tirzepatide versus placebo or semaglutide on pancreatic islet function and insulin sensitivity in adults with type 2 diabetes: a multicentre, randomised, double-blind, parallel-arm, phase 1 clinical trial
- (2022) Tim Heise et al. Lancet Diabetes & Endocrinology
- Not Control but Conquest: Strategies for the Remission of Type 2 Diabetes Mellitus
- (2022) Jinyoung Kim et al. Diabetes & Metabolism Journal
- TRC150094, a Novel Mitochondrial Modulator, Reduces Cardio-Metabolic Risk as an Add-On Treatment: a Phase-2, 24-Week, Multi-Center, Randomized, Double-Blind, Clinical Trial
- (2022) Deepa Joshi et al. Diabetes Metabolic Syndrome and Obesity-Targets and Therapy
- The Correlation of Prediabetes and Type 2 Diabetes With Adiposity in Adults
- (2022) Juan Sun et al. Frontiers in Nutrition
- Brown and beige adipose tissue: a novel therapeutic strategy for obesity and type 2 diabetes mellitus
- (2021) Long Cheng et al. Adipocyte
- The PRISMA 2020 statement: an updated guideline for reporting systematic reviews
- (2021) Matthew J Page et al. BMJ-British Medical Journal
- Glucagon‐like peptide‐1 in diabetes care: Can glycaemic control be achieved without nausea and vomiting?
- (2021) Tito Borner et al. BRITISH JOURNAL OF PHARMACOLOGY
- Emerging glucagon-like peptide 1 receptor agonists for the treatment of obesity
- (2021) Mathies M. Jepsen et al. EXPERT OPINION ON EMERGING DRUGS
- Combined medical strategies for the management of type 2 diabetes mellitus and obesity in adults
- (2021) Mohamad Sirri Tarazi et al. EXPERT OPINION ON PHARMACOTHERAPY
- Dietary strategies for remission of type 2 diabetes: A narrative review
- (2021) Adrian Brown et al. JOURNAL OF HUMAN NUTRITION AND DIETETICS
- Efficacy and safety of a novel dual GIP and GLP-1 receptor agonist tirzepatide in patients with type 2 diabetes (SURPASS-1): a double-blind, randomised, phase 3 trial
- (2021) Julio Rosenstock et al. LANCET
- Once-weekly tirzepatide versus once-daily insulin degludec as add-on to metformin with or without SGLT2 inhibitors in patients with type 2 diabetes (SURPASS-3): a randomised, open-label, parallel-group, phase 3 trial
- (2021) Bernhard Ludvik et al. LANCET
- Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes
- (2021) Juan P. Frías et al. NEW ENGLAND JOURNAL OF MEDICINE
- Anti-diabetic drugs and weight loss in patients with type 2 diabetes
- (2021) Elisa Lazzaroni et al. PHARMACOLOGICAL RESEARCH
- A phase 1 multiple‐ascending dose study of tirzepatide in Japanese participants with type 2 diabetes
- (2021) Kenichi Furihata et al. DIABETES OBESITY & METABOLISM
- Effects of Tirzepatide, a Dual GIP and GLP-1 RA, on Lipid and Metabolite Profiles in Subjects With Type 2 Diabetes
- (2021) Valentina Pirro et al. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
- Efficacy and Safety of Tirzepatide in Patients with Type 2 Diabetes Mellitus: A Systematic Review and Meta-Analysis of Randomized Phase II/III Trials
- (2021) Akshaya Srikanth Bhagavathula et al. Pharmaceuticals
- Standards of Medical Care in Diabetes—2022 Abridged for Primary Care Providers
- (2021) Clinical Diabetes
- The dual glucose‐dependent insulinotropic peptide and glucagon‐like peptide‐1 receptor agonist, tirzepatide, improves lipoprotein biomarkers associated with insulin resistance and cardiovascular risk in patients with type 2 diabetes
- (2020) Jonathan M. Wilson et al. DIABETES OBESITY & METABOLISM
- Dual GIP and GLP-1 Receptor Agonist Tirzepatide Improves Beta-cell Function and Insulin Sensitivity in Type 2 Diabetes
- (2020) Melissa K Thomas et al. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
- The Role of Tirzepatide, Dual GIP and GLP-1 Receptor Agonist, in the Management of Type 2 Diabetes: The SURPASS Clinical Trials
- (2020) Thinzar Min et al. Diabetes Therapy
- Separate and Combined Gluco-Metabolic Effects of Endogenous Glucose-Dependent Insulinotropic Polypeptide and Glucagon-Like Peptide-1 in Healthy Individuals
- (2019) Lærke S. Gasbjerg et al. DIABETES
- Glucose-Dependent Insulinotropic Polypeptide Receptor-Expressing Cells in the Hypothalamus Regulate Food Intake
- (2019) Alice E. Adriaenssens et al. Cell Metabolism
- 8. Obesity Management for the Treatment of Type 2 Diabetes: Standards of Medical Care in Diabetes—2020
- (2019) DIABETES CARE
- Insulin therapy, weight gain and prognosis
- (2018) Israel Hodish DIABETES OBESITY & METABOLISM
- Dorzagliatin monotherapy in Chinese patients with type 2 diabetes: a dose-ranging, randomised, double-blind, placebo-controlled, phase 2 study
- (2018) Dalong Zhu et al. Lancet Diabetes & Endocrinology
- Efficacy and Safety of Once-weekly Dulaglutide Versus Insulin Glargine in Mainly Asian Patients with Type 2 Diabetes Mellitus on Metformin and/or a Sulfonylurea: a 52-week Open-label, Randomized Phase 3 Trial
- (2018) Weiqing Wang et al. DIABETES OBESITY & METABOLISM
- Efficacy and safety of LY3298176, a novel dual GIP and GLP-1 receptor agonist, in patients with type 2 diabetes: a randomised, placebo-controlled and active comparator-controlled phase 2 trial
- (2018) Juan Pablo Frias et al. LANCET
- Does obesity cause type 2 diabetes mellitus (T2DM)? Or is it the opposite?
- (2018) John I. Malone et al. PEDIATRIC DIABETES
- Global aetiology and epidemiology of type 2 diabetes mellitus and its complications
- (2017) Yan Zheng et al. Nature Reviews Endocrinology
- rDNA insulin glargine U300 – a critical appraisal
- (2016) Fei Wang et al. Diabetes Metabolic Syndrome and Obesity-Targets and Therapy
- Therapeutic Use of Metformin in Prediabetes and Diabetes Prevention
- (2015) Ulrike Hostalek et al. DRUGS
- Impact of GLP-1 Receptor Agonists on Major Gastrointestinal Disorders for Type 2 Diabetes Mellitus: A Mixed Treatment Comparison Meta-Analysis
- (2012) Feng Sun et al. Experimental Diabetes Research
- Basal Insulin: Physiology, Pharmacology, and Clinical Implications
- (2011) Kevin D. Niswender POSTGRADUATE MEDICINE
- Insulin glargine and its role in glycaemic management of Type 2 diabetes
- (2008) MA Elrishi et al. Expert Opinion on Drug Metabolism & Toxicology
Find the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
SearchAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started